Associations of demographic and perinatal factors with childhood neuroblastoma in Texas, 1995–2011 |
| |
| Institution: | 1. Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA;2. Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Houston, TX, USA;3. Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA;4. Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA;1. Department of Urology, New York University Grossman School of Medicine, New York, NY, United States;2. Department of Urology, SUNY Downstate Health Sciences Campus, Brooklyn, NY, United States;3. Department of Population Health, New York University Grossman School of Medicine, New York, NY, United States;4. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United States;5. Department of Urology, University of North Carolina, Chapel Hill, NC, United States;6. VA NY Harbor Healthcare System, United States;7. Department of Surgery, Urology Service; Memorial Sloan Kettering Cancer Center;1. Department of Surgery and Endoscopy, Tenwek Hospital, Bomet, Kenya;2. Department of Surgery, Alpert Medical School of Brown University, Providence, RI, USA;3. Biostatistics Branch, Division of Cancer and Epidemiology, National Cancer Institute, Rockville, MD, USA;4. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA;5. Department of Pathology, University of Nairobi, Nairobi, Kenya;6. Mayo Clinic, Rochester, MN, USA;1. HCA Florida Brandon Hospital Department of Internal Medicine, 119 Oakfield Drive, Brandon, FL 33511, USA;2. University of Kansas School of Medicine Department of Population Health, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA;3. University of Kansas Cancer Center, 4000 Cambridge Street, Kansas City, KS 66160, USA;1. Department of Cancer Strategy, Cancer Control Center, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka City, Osaka Prefecture 541-8567, Japan;2. Inequalities in Cancer Outcome Network, Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom;9. Registre des Cancers du Sein et Cancers Gynécologiques de Côte d’Or, France;10. Registre général des cancers de la Manche, France;11. Registre bourguignon des cancers digestifs, France;12. MSA Gironde, France;13. Registre général des cancers de l’Isère, France;14. Registre général des cancers de la Gironde, France;15. MSA Midi-Pyrénées Nord, France;p. Registre général des cancers du Tarn, France;q. Registre général des tumeurs du Calvados, France;r. MSA Alsace, France;s. MSA Franche Comté, France;t. Registre général des cancers de la Somme, France;u. Registre des tumeurs digestives du Calvados, France;v. MSA Bourgogne, France;w. Registre général des cancers du HautRhin, France;x. Caisse centrale de la MSA, France;y. Registre des hémopathies malignes Côte d’Or, France;z. Registre général de la Loire-Atlantique et Vendée, France;11. Registre des hémopathies malignes de la Gironde, France;12. MSA Picardie, France;13. MSA Côtes Normandes, France;14. MSA Alpes du Nord, France;15. Registre régional des hémopathies malignes de Basse Normandie, France;16. Registre général des cancers du Bas-Rhin, France;17. MSA Loire-Atlantique Vendée, France;18. Registre général des tumeurs du Doubs, France;1. Institut national de la santé et de la recherche médicale (INSERM), Unité mixte de recherche (UMR) 1086 ANTICIPE, Caen, France;2. Centre de Lutte Contre le Cancer François Baclesse, Caen, France;3. University of Caen Normandy, Caen, France;4. Calvados Digestive Cancer Registry, France;5. Epidemiology Research and Evaluation Unit – UMR 1086 INSERM-UCN Anticipe, University Hospital of Caen, Avenue de la Côte de Nacre, 14033 Caen Cedex, France;6. CHU de Caen, Service de Pathologie Professionnelle, Caen, France;7. EPICENE team, ISPED, INSERM U1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France;8. CHU de Bordeaux, Service de Médecine du Travail et Pathologies Professionnelles, Bordeaux, France;1. Department of Preventive Medical Sciences, Fujita Health University School of Medical Sciences, Toyoake, Aichi 470-1192, Japan;2. Department of Hygiene, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan;3. Department of Biochemistry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan;4. Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761-0123, Japan;5. Department of Informative Clinical Medicine, Fujita Health University School of Medical Sciences, Toyoake, Aichi 470-1192, Japan;6. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan |
| |
| Abstract: | BackgroundNeuroblastoma, the most common extracranial solid tumor in children, contributes disproportionately to childhood cancer mortality and few risk factors have been identified. Our objective was to evaluate associations between parental and infant characteristics and neuroblastoma incidence.MethodsChildren born in Texas between January 1995 and December 2011 were eligible for the present study. Cases (N = 637) were diagnosed with neuroblastoma in Texas during the same period; controls (N = 6370) matched on year of birth were randomly selected from birth certificates that did not link to a record in the Texas Cancer Registry. We obtained data on birth and parental demographic/reproductive characteristics from birth certificates, and estimated odds ratios (OR) and 95% confidence intervals (CIs) for neuroblastoma using logistic regression.ResultsGestational age 34–36 weeks at birth was associated with neuroblastoma (OR 1.45, CI 1.09–1.90), whereas female sex was inversely associated (OR 0.68, CI 0.58–0.81). Relative to children of non-Hispanic White women, children of Hispanic (OR 0.53, CI 0.43–0.64) or non-Hispanic Black (OR 0.52, CI 0.38–0.71) women were at reduced odds of neuroblastoma. When maternal and paternal race/ethnicity were evaluated jointly, similar patterns were observed (two non-Hispanic Black parents: OR 0.55, 95%CI 0.36–0.79; two Hispanic parents: OR 0.53, 95%CI 0.41–0.67). Older maternal age was also positively associated with neuroblastoma (OR 1.41, CI 1.04–1.90 for 35–39 years; OR 1.62, CI 0.87–2.81 for ≥40 years, relative to 25–29 years).ConclusionsFindings provide further evidence of racial/ethnic disparities in neuroblastoma incidence, determinants of which are unknown. In contrast to most published studies, we observed an association between maternal age and neuroblastoma. Further studies with more robust control for confounding are warranted. |
| |
| Keywords: | Neuroblastoma Epidemiology Childhood cancer Cancer disparities |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
